Back to Authors

Jenkins, Robert B.

https://orcid.org/0000-0002-4049-694X

Mayo Clinic

Mayo Clinic

Citations 275

TMOD-34. IMPROVED TREATMENT OF MELANOMA BRAIN METASTASIS USING A SYNTHETIC PEPTIDE
Aasen, Synnøve Nymark , Maherally, Zaynah, Miletić, Hrvoje , Eikeland, Anne Vaag, Bjerkvig, Rolf , Olberg, Dag Erlend , Sarkar, Gobinda , Jenkins, Robert B. , Espedal, Heidi , Holte, Christopher Florian , Keunen, Olivier , Karlsen, Tine V. , Tenstad, Olav , Baghirov, Habib , Thorsen, Frits

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi275-vi276

10.1093/neuonc/noy148.1146 Get It

COMP-05. EVALUATION OF A DEEP LEARNING ARCHITECTURE FOR MRI PREDICTION OF IDH, 1p19q AND TERT IN GLIOMA PATIENTS
Korfiatis, Panagiotis , Buckner, Jan C. , Eckel‐Passow, Jeanette E. , Decker, Paul A. , Jenkins, Robert B. , Wrensch, Margaret , Wiencke, John, Hansen, Helen, Rice, Terri, McCoy, Lucie , Nelson, Sarah J. , Clarke, Jennifer , Taylor, Jennie , Luks, Tracy , Lachance, Daniel Honore , Parney, Ian F. , Decker, Paul A. , Wiencke, John K. , Hansen, Helen M. , Erickson, Bradley J.

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi64-vi64

10.1093/neuonc/noy148.260 Get It

PATH-26. NEURO-ONCOLOGY NEXT-GENERATION SEQUENCING 219-GENE PANEL FOR COMPREHENSIVE CLINICAL TESTING
Fritcher, Emily Barr, Zysk, Christopher, Voss, Jesse S. , Wu, Xianglin, Klee, Eric W. , Kipp, Benjamin R. , Jenkins, Robert B. , Ida, Cristiane M. , Fritcher, Emily G. Barr , Balan, Jagadheshwar , Kollmeyer, Thomas M. , Raghunathan, Aditya , Giannini, Caterina

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi164-vi164

10.1093/neuonc/noy148.682 Get It

PATH-24. RECURRENT UNUSUAL PATTERNS IN CLINICAL MOLECULAR PROFILING OF ADULT DIFFUSE GLIOMAS
Mendoza, Cinthya Zepeda, Balcom, Jessica R. , Swanson, Kirsten, Fritcher, Emily Barr, Parisi, Joseph E., Jentoft, Mark E. , Kipp, Benjamin R. , Jenkins, Robert B. , Ida, Cristiane M. , Zepeda‐Mendoza, Cinthya , Praska, Corinne , Fritcher, Emily G. Barr , Geiersbach, Katherine B. , Raghunathan, Aditya , Giannini, Caterina

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi163-vi163

10.1093/neuonc/noy148.680 Get It

GENE-11. SMALL TERMINAL ALTERATIONS AND ALTERNATIVE LENGTHENING OF TELOMERES ARE A FEATURE OF IDH-MUTANT, 1p/19q NON-CODELETED GLIOMAS
Yamada, Seiji , Jacobs, Joshua , Decker, Paul A. , Kosel, Matt, Caron, Alissa, Halder, Chandralekha, Ruiz, Vanessa , Kipp, Benjamin R. , Voss, Jesse S. , Vaubel, Rachel, Jenkins, Robert B. , Brown, Desmond , Praska, Corinne , Kollmeyer, Thomas M. , Decker, Paul A. , Kosel, Matthew , Giannini, Caterina

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi105-vi105

10.1093/neuonc/noy148.438 Get It

GENE-29. DLL3 AND ETV1 ARE INACTIVATED/METHYLATED IN CIC WILD-TYPE, IDH-MUTATED, 1p/19q-CODELETED GLIOMA
Kosel, Matthew , Decker, Paul A. , Caron, Alissa, Sarkar, Gobinda , Halder, Chandralekha, Tian, Shulan , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Lachance, Daniel Honore , Decker, Paul A. , Kollmeyer, Thomas M. , Drucker, Kristen , Knight, Andrew, Abyzov, Alexej , Burns, Terry C. , Giannini, Caterina

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi109-vi109

10.1093/neuonc/noy148.455 Get It

TMOD-18. THE PATIENT DERIVED XENOGRAFT NATIONAL RESOURCE: A COMPREHENSIVE COLLECTION OF HIGH-GRADE GLIOMA MODELS FOR PRE-CLINICAL AND TRANSLATIONAL STUDIES
Tian, Shulan , Peng, Sen, Carlson, Brett L. , Kitange, Gaspar J. , Evers, Lisa, Decker, Paul A. , Kosel, Matthew , Klee, Eric W. , James, C. David , Eckel‐Passow, Jeanette E. , Verhaak, Roel G.W. , Jenkins, Robert B. , Vaubel, Rachael A. , Remonde, Dioval , Schroeder, Mark A. , Kollmeyer, Thomas M. , Mladek, Ann C. , Daniel, J. , Decker, Paul A. , Berens, Michael E. , Califano, Andrea , Lachance, Daniel Honore , Sulman, Erik P. , Tran, Nhan L. , Giannini, Caterina , Parney, Ian F. , Sarkaria, Jann N.

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi272-vi272

10.1093/neuonc/noy148.1130 Get It

Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia
Aypar, Umut , Smoley, Stephanie A., Pitel, Beth A. , Pearce, Kathryn E., Zenka, Roman M. , Vasmatzis, George , Johnson, Sarah H. , Smadbeck, James B. , Peterson, Jess F. , Geiersbach, Katherine B. , Dyke, Daniel L. Van , Thorland, Erik C., Jenkins, Robert B. , Greipp, Patricia T. , Kearney, Hutton M. , Hoppman, Nicole L., Van Dyke, Daniel L, Peterson, Jess F , Pitel, Beth A , Greipp, Patricia T , Ketterling, Rhett P. , Baughn, Linda B. , Aypar, Umut , Geiersbach, Katherine

European Journal of Haematology | October 1, 2018 | Volume: 102 | Issue: 1 | Pages: 87-96

10.1111/ejh.13179 Get It

AbstractObjectiveAcute myeloid leukemia (AML) can be subtyped based on recurrent cytogenetic and molecular genetic abnormalities with diagnostic and prognostic significance. Although cytogenetic characterization classically involves conventional chromosome and/or fluorescence in situ hybridization (FISH) assays, limitations of these techniques include poor resolution and the inability to precisely identify breakpoints.MethodWe evaluated whether an NGS‐based methodology that detects structural abnormalities and copy number changes using mate pair sequencing (MPseq) can enhance the diagnostic yield for patients with AML.ResultsUsing 68 known abnormal and 20 karyotypically normal AML samples, each recurrent primary AML‐specific abnormality previously identified in the abnormal samples was confirmed using MPseq. Importantly, in eight cases with abnormalities that could not be resolved by conventional cytogenetic studies, MPseq was utilized to molecularly define eight recurrent AML‐fusion events. In addition, MPseq uncovered two cryptic abnormalities that were missed by conventional cytogenetic studies. Thus, MPseq improved the diagnostic yield in the detection of AML‐specific structural rearrangements in 10/88 (11%) of cases analyzed.ConclusionUtilization of MPseq represents a precise, molecular‐based technique that can be used as an alternative to conventional cytogenetic studies for newly diagnosed AML patients with the potential to revolutionize the diagnosis of hematologic malignancies.